Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Jazz Pharmaceuticals PLC (JAZZ : NSDQ)

• Company Description    Jazz Pharmaceuticals is a specialty biopharmaceutical company with a focus in the areas of neuroscience & oncology. It derives the majority of its revenues from its sleep disorder drugs' Xywav & Xyrem. Both drugs are approved for treating cataplexy & excessive daytime sleepiness in narcolepsy patients. Other drugs in the company's neuroscience portfolio include' Sunosi, Epidiolex & Sativex. Epidiolex is approved for treating seizures associated with two rare & severe forms of epilepsy' Lennox-Gastaut syndrome & Dravet syndrome. Sativex is approved in the U.K. & Canada as a treatment for symptom improvement in adult patients with moderate-to-severe spasticity due to multiple sclerosis. Jazz's oncology portfolio includes two drugs' Defitelio for the treatment hepatic veno-occlusive disease with renal or pulmonary dysfunction following hematopoietic stem cell transplantation & Vyxeos for the treatment of adults with two types of acute myeloid leukemia. It received approval for two new drugs' Zepzelca & Rylaze'. Number of Employees: 2,800

• Price / Volume Information    Yesterday's Closing Price: $170.00 Daily Weekly Monthly 20 Day Moving Average: 794,383 shares Shares Outstanding: 60.76 (millions) Market Capitalization: $10,330.07 (millions) Beta: 0.27 52 Week High: $182.99 52 Week Low: $95.49 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.85% 2.02% 12 Week 23.06% 21.07% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL FIFTH FLOOR WATERLOO EXCHANGE WATERLOO ROAD - DUBLIN,L2 D04 E5W7 IRL ph: 011-353-1634-7800 fax: 353-1634-7850 investorinfo@jazzpharma.com http://www.jazzpharma.com

• General Corporate Information    Officers Bruce C. Cozadd - Chief Executive Officer; Chairman and Director Philip L. Johnson - Executive Vice President and Chief Financial Offic Patricia Carr - Senior Vice President Jennifer E. Cook - Director Patrick G. Enright - Director Peer Information Jazz Pharmaceuticals PLC (CORR.) Jazz Pharmaceuticals PLC (RSPI) Jazz Pharmaceuticals PLC (CGXP) Jazz Pharmaceuticals PLC (BGEN) Jazz Pharmaceuticals PLC (GTBP) Jazz Pharmaceuticals PLC (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: G50871105 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/24/26 Share - Related Items Shares Outstanding: 60.76 Most Recent Split Date: (:1) Beta: 0.27 Market Capitalization: $10,330.07 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $3.69 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $19.47 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 8.00 Change In Payout Ratio: 0.00 Estmated Long-Term EPS Growth Rate: 11.00% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/24/26

• Fundamental Ratios P/E Current FY Estimate: 8.73 Trailing 12 Months: 40.28 PEG Ratio: 0.79 Price Ratios Price/Book: 2.61 Price/Cash Flow: 5.60 Price / Sales: 2.48 EPS Growth vs. Year Ago Period: 19.28% vs. Previous Quarter: 177.07% Sales Growth vs. Year Ago Period: 6.74% vs. Previous Quarter: 7.69% ROE 12/31/25 - - 09/30/25 - 6.61 06/30/25 - 5.02 ROA 12/31/25 - - 09/30/25 - 2.30 06/30/25 - 1.73 Current Ratio 12/31/25 - - 09/30/25 - 1.65 06/30/25 - 1.62 Quick Ratio 12/31/25 - - 09/30/25 - 1.44 06/30/25 - 1.37 Operating Margin 12/31/25 - - 09/30/25 - 6.33 06/30/25 - 4.96 Net Margin 12/31/25 - - 09/30/25 - -8.86 06/30/25 - -9.91 Pre-Tax Margin 12/31/25 - - 09/30/25 - -16.91 06/30/25 - -12.51 Book Value 12/31/25 - - 09/30/25 - 65.15 06/30/25 - 61.10 Inventory Turnover 12/31/25 - - 09/30/25 - 0.98 06/30/25 - 0.91 Debt-to-Equity 12/31/25 - - 09/30/25 - 1.09 06/30/25 - 1.17 Debt-to-Capital 12/31/25 - - 09/30/25 - 52.25 06/30/25 - 53.91

Powered by Zacks Investment Research ©